open access
Efficacy of therapy and secondary prophylaxis of deep vein thrombosis with low-molecular-weight heparin
open access
Abstract
Material and methods: A group of 20 patients with proximal deep vein thrombosis (studied group-SG), in whom DVT was accompanied by cancer, and one of 30 patients with proximal DVT without malignancy jedsymptoms (control group-CG) were studied. The treatment protocol assumed DVT treatment with LMWH (nadroparin) during a 6-month period in both groups. The drug was administered subcutaneously in a twice daily dose 0.1 ml per 10 kg every 12 hours for the first 10 days and subsequently 0.1 ml per 10 kg once daily for a 6-month period. The assessment of treatment results was based on venography and Doppler ultrasound scans. The incidence of complications was analyzed.
Results: The study results showed no statistically significant differences in the treatment results between both groups. The lack of complete venous vessel recanalization was indicated in both groups after a 6-month therapy. No serious complications in either group was observed.
Conclusions: Our current study suggests that LMWH in secondary prophylaxis, in a dose equal to half of the therapeutic dose, is a safe and effective alternative to oral anticoagulants in patients with coexisting malignant disease.
Abstract
Material and methods: A group of 20 patients with proximal deep vein thrombosis (studied group-SG), in whom DVT was accompanied by cancer, and one of 30 patients with proximal DVT without malignancy jedsymptoms (control group-CG) were studied. The treatment protocol assumed DVT treatment with LMWH (nadroparin) during a 6-month period in both groups. The drug was administered subcutaneously in a twice daily dose 0.1 ml per 10 kg every 12 hours for the first 10 days and subsequently 0.1 ml per 10 kg once daily for a 6-month period. The assessment of treatment results was based on venography and Doppler ultrasound scans. The incidence of complications was analyzed.
Results: The study results showed no statistically significant differences in the treatment results between both groups. The lack of complete venous vessel recanalization was indicated in both groups after a 6-month therapy. No serious complications in either group was observed.
Conclusions: Our current study suggests that LMWH in secondary prophylaxis, in a dose equal to half of the therapeutic dose, is a safe and effective alternative to oral anticoagulants in patients with coexisting malignant disease.
Keywords
deep vein thrombosis; heparin; malignant diseases
About this articleTitle
Efficacy of therapy and secondary prophylaxis of deep vein thrombosis with low-molecular-weight heparin
Journal
Chirurgia Polska (Polish Surgery)
Issue
Pages
43-52
Published online
2005-05-06
Bibliographic record
Chirurgia Polska 2005;7(1):43-52.
Keywords
deep vein thrombosis
heparin
malignant diseases
Authors
Zbigniew Krasiński
Grzegorz Oszkinis
Ryszard Staniszewski
Krzysztof Lewandowski
Rodryg Ramlau
Beata Krasińska
Marcin Gabriel
Mirosław Czyżak
Wacław Majewski
